Clinical trials: Neuroendocrine Tumor Grade 1
Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers.
- Trial name
- NCT06228066
- Testing
- Lurbinectedin, Avelumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places…
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma
- Trial name
- NCT03728361
- Testing
- Nivolumab, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Dwight Owen
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
This is a first in man study to determine if [203Pb]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy in neuroendocrine therapy.
- Trial name
- NCT05111509
- Testing
- [203Pb]VMT-α-NET, SPECT/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yusuf Menda
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumor of Pancreas (Disorder), Neuroendocrine Tumor Grade 1
Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors
Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing…
- Trial name
- RFANET (NCT04520932)
- Testing
- Radiofrequency ablation
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
Neuroendocrine Tumors
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Clinical data from uncontrolled retrospective or prospective studies have initially demonstrated antiproliferative effects of lanreotide in limited number of patients lanreotide Autogel® has recently been approved in more than 40…
- Trial name
- NCT03083210
- Testing
- Lanreotide
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants…
- Trial name
- NCT04471727
- Testing
- Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
- Where
- 11 sites in United States
- Volunteers
- 232 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Neoplasm, Pancreas Adenocarcinoma
Pancreatic Cancer Dietary Assessment Study
This is a prospective observational study which aims to evaluate; The prevalence of pancreatic insufficiency in patients with pancreatic malignancies (adenocarcinoma and neuroendocrine tumours).
- Conditions
- Pancreatic Neoplasm, Pancreas Adenocarcinoma, Well-Differentiated Neuroendocrine Carcinoma, Malignant Neoplasm of Pancreas
- Trial name
- PanDA (NCT03616431)
- Testing
- Pancreo-KIT breath test
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- The Christie NHS Foundation Trust
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Neuroendocrine Tumors, Everolimus
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B.
- Trial name
- NCT03014297
- Testing
- everolimus, fosbretabulin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Lowell Anthony, MD
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments.
- Conditions
- Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract
- Trial name
- NCT06161532
- Testing
- Sacituzumab govitecan, Atezolizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neuroendocrine Tumors, WHO Grade I-II
Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
A national multicenter prospective study to investigate the feasibility and efficacy of endoscopic ultrasound guided radiofrequency ablation of neuroendocrine pancreatic tumors, WHO Grade 1-2 of 3 cm or less in diameter.
- Trial name
- ERFA-PNET (NCT05243082)
- Testing
- Radio frequency ablation
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital